| Patient | Booker T. Washington |
|---|---|
| Date of birth | 1856-04-05 |
| Identifiers | MRN HR-NI017-SYN-TD; SSN (made up) 000-17-2284 |
| Document date | 2026-11-01 |
| Author | Lorraine Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for headaches, fatigue, and a very high blood pressure. Concerns: Frontal headaches every week or so, palpitations, and fatigue are cutting into his workday; Worried about blurred reading vision and getting up at night to urinate; Wants a plan that fits a heavy travel schedule. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-04 | active | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-04 to 1915-05-11 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-11 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-11 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily | One-half tablet by mouth daily | Oral route | 1915-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-04 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| 12-lead electrocardiogram: sinus rhythm with left ventricular hypertrophy by voltage | 1915-05-04 to 1915-05-04 | completed | S |
| Dilated funduscopic examination: arteriolar narrowing and arteriovenous nicking in both eyes; no hemorrhages, exudates, or papilledema | 1915-05-04 to 1915-05-04 | completed | S |
| Renal ultrasound: both kidneys small (9.4 and 9.6 cm) and echogenic, without hydronephrosis | 1915-05-11 to 1915-05-11 | completed | S |
| Transthoracic echocardiography: concentric left ventricular hypertrophy, ejection fraction 60 percent | 1915-05-11 to 1915-05-11 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1914-10-20 | Influenza vaccine, 1914-1915 season | completed | S |
| 1915-05-11 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1915-05-11 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 1915-06-29 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 1908-09-16 | Tdap vaccine | completed | S |
| 1915-09-21 | Influenza vaccine, 1915-1916 season | completed | S |
| 1915-09-21 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1911 | Assault in New York City with two large scalp lacerations and a torn ear; recovered without apparent sequelae | D (CLM-0005) |
| 1911 | Chronic indigestion, worse when traveling; several days of treatment at the Battle Creek Sanitarium in 1911 | D (CLM-0005) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died in Malden, West Virginia, in 1876 (other accounts give 1874); cause not recorded in the cited source | D (CLM-0003) |
| Concern | Status | Evidence |
|---|---|---|
| Frontal headaches every week or so, palpitations, and fatigue are cutting into his workday | active | S |
| Worried about blurred reading vision and getting up at night to urinate | active | S |
| Wants a plan that fits a heavy travel schedule | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 137 on 1915-08-10; Potassium [Moles/volume] in Serum or Plasma 4.7 on 1915-08-10; Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 on 1915-08-10; Urea nitrogen [Mass/volume] in Serum or Plasma 37 on 1915-08-10; Creatinine [Mass/volume] in Serum or Plasma 2.4 on 1915-08-10; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M 30 on 1915-08-10; Glucose [Mass/volume] in Serum or Plasma 94 on 1915-08-10; Calcium [Mass/volume] in Serum or Plasma 9.2 on 1915-10-26; Phosphate [Mass/volume] in Serum or Plasma 4 on 1915-10-26; Parathyrin.intact [Mass/volume] in Serum or Plasma 78 on 1915-10-26; Hemoglobin [Mass/volume] in Blood 12.8 on 1915-10-26; Ferritin [Mass/volume] in Serum or Plasma 210 on 1915-05-04; Iron saturation [Mass Fraction] in Serum or Plasma 26 on 1915-05-04; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 1915-05-04; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 1915-05-04; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 138 on 1915-05-04; Albumin/Creatinine [Mass Ratio] in Urine 240 on 1915-10-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 1915-09-21; Kidney failure 2-year risk [Likelihood] by KFRE 6.5 on 1915-10-26; Kidney failure 5-year risk [Likelihood] by KFRE 18.8 on 1915-10-26; Left ventricular Ejection fraction 60 on 1915-05-11; Total score [AUDIT-C] 1 on 1915-09-21 [S]
Strengths and supports: Supports: spouse, adult children, and long-time colleagues who urged him to be seen [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1804 blood pressure of 220/150 | active | confirmed | I12.9 | S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R. |
| Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis | active | confirmed | N18.32 | S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease. |
| Hypertensive retinopathy, both eyes, without papilledema | active | confirmed | H35.033 | S — Synthetic funduscopic finding that echoes the documented failing vision. |
| Mild anemia of chronic kidney disease, iron replete; monitor | active | confirmed | D63.1 | S — Synthetic finding from the baseline hemoglobin and iron studies. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| Acute lumbar muscle strain after lifting, resolved without NSAIDs or imaging | resolved | confirmed | S39.012A | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1915-05-04 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1915-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1915-05-04 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 21 | mmol/L | 22-29 mmol/L | Low | S |
| 1915-05-04 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 | mg/dL | 6-24 mg/dL | High | S |
| 1915-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 2.1 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1915-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 36 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1915-05-04 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 1915-05-04 | Calcium [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1915-05-04 | Phosphate [Mass/volume] in Serum or Plasma | 4.2 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1915-05-04 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 92 | pg/mL | 15-65 pg/mL | High | S |
| 1915-05-04 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1915-05-04 | Ferritin [Mass/volume] in Serum or Plasma | 210 | ng/mL | 30-400 ng/mL | Normal | S |
| 1915-05-04 | Iron saturation [Mass Fraction] in Serum or Plasma | 26 | % | 20-50% | Normal | S |
| 1915-05-04 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1915-05-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | <=5.6% | Normal | S |
| 1915-05-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 138 | mg/dL | <=99 mg/dL | High | S |
| 1915-05-04 | Albumin/Creatinine [Mass Ratio] in Urine | 820 | mg/g | <=30 mg/g | High | S |
| 1915-05-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1915-05-11 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1915-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1915-05-11 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | 22-29 mmol/L | Normal | S |
| 1915-05-11 | Urea nitrogen [Mass/volume] in Serum or Plasma | 36 | mg/dL | 6-24 mg/dL | High | S |
| 1915-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 2.2 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1915-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 34 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1915-05-11 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 1915-06-01 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1915-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1915-06-01 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | 22-29 mmol/L | Normal | S |
| 1915-06-01 | Urea nitrogen [Mass/volume] in Serum or Plasma | 38 | mg/dL | 6-24 mg/dL | High | S |
| 1915-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1915-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 30 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1915-06-01 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1915-06-29 | Sodium [Moles/volume] in Serum or Plasma | 135 | mmol/L | 135-145 mmol/L | Normal | S |
| 1915-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1915-06-29 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 1915-06-29 | Urea nitrogen [Mass/volume] in Serum or Plasma | 36 | mg/dL | 6-24 mg/dL | High | S |
| 1915-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1915-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 30 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1915-06-29 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 1915-06-29 | Albumin/Creatinine [Mass Ratio] in Urine | 360 | mg/g | <=30 mg/g | High | S |
| 1915-10-26 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 1915-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1915-10-26 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 1915-10-26 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 | mg/dL | 6-24 mg/dL | High | S |
| 1915-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 2.3 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1915-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 32 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1915-10-26 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 1915-10-26 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1915-10-26 | Phosphate [Mass/volume] in Serum or Plasma | 4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1915-10-26 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 78 | pg/mL | 15-65 pg/mL | High | S |
| 1915-10-26 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1915-10-26 | Albumin/Creatinine [Mass Ratio] in Urine | 240 | mg/g | <=30 mg/g | High | S |
| 1915-10-26 | Kidney failure 2-year risk [Likelihood] by KFRE | 6.5 | % | S | ||
| 1915-10-26 | Kidney failure 5-year risk [Likelihood] by KFRE | 18.8 | % | S | ||
| 1915-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 1915-05-11 | Left ventricular Ejection fraction | 60 | % | 50-70% | Normal | S |
| 1915-08-10 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1915-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1915-08-10 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 1915-08-10 | Urea nitrogen [Mass/volume] in Serum or Plasma | 37 | mg/dL | 6-24 mg/dL | High | S |
| 1915-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1915-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 30 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1915-08-10 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1915-09-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 1915-09-21 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1915-05-04 | Body height | 170 | cm | S |
| 1915-05-04 | Body weight | 71 | kg | S |
| 1915-05-04 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 1915-05-04 | Systolic blood pressure | 212 | mm[Hg] | S |
| 1915-05-04 | Diastolic blood pressure | 128 | mm[Hg] | S |
| 1915-05-04 | Heart rate | 88 | /min | S |
| 1915-05-04 | Respiratory rate | 16 | /min | S |
| 1915-05-04 | Body temperature | 36.8 | Cel | S |
| 1915-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1915-05-11 | Body height | 170 | cm | S |
| 1915-05-11 | Body weight | 71 | kg | S |
| 1915-05-11 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 1915-05-11 | Systolic blood pressure | 172 | mm[Hg] | S |
| 1915-05-11 | Diastolic blood pressure | 104 | mm[Hg] | S |
| 1915-05-11 | Heart rate | 82 | /min | S |
| 1915-05-11 | Respiratory rate | 16 | /min | S |
| 1915-05-11 | Body temperature | 36.7 | Cel | S |
| 1915-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1915-06-01 | Body height | 170 | cm | S |
| 1915-06-01 | Body weight | 70 | kg | S |
| 1915-06-01 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 1915-06-01 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1915-06-01 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 1915-06-01 | Heart rate | 78 | /min | S |
| 1915-06-01 | Respiratory rate | 16 | /min | S |
| 1915-06-01 | Body temperature | 36.8 | Cel | S |
| 1915-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1915-06-29 | Body height | 170 | cm | S |
| 1915-06-29 | Body weight | 70 | kg | S |
| 1915-06-29 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 1915-06-29 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1915-06-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1915-06-29 | Heart rate | 74 | /min | S |
| 1915-06-29 | Respiratory rate | 14 | /min | S |
| 1915-06-29 | Body temperature | 36.7 | Cel | S |
| 1915-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1915-10-26 | Body height | 170 | cm | S |
| 1915-10-26 | Body weight | 70.5 | kg | S |
| 1915-10-26 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 1915-10-26 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1915-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1915-10-26 | Heart rate | 72 | /min | S |
| 1915-10-26 | Respiratory rate | 14 | /min | S |
| 1915-10-26 | Body temperature | 36.6 | Cel | S |
| 1915-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1915-08-10 | Body height | 170 | cm | S |
| 1915-08-10 | Body weight | 70.3 | kg | S |
| 1915-08-10 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 1915-08-10 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1915-08-10 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1915-08-10 | Heart rate | 80 | /min | S |
| 1915-08-10 | Respiratory rate | 14 | /min | S |
| 1915-08-10 | Body temperature | 36.7 | Cel | S |
| 1915-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1915-09-21 | Body height | 170 | cm | S |
| 1915-09-21 | Body weight | 70.4 | kg | S |
| 1915-09-21 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 1915-09-21 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1915-09-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1915-09-21 | Heart rate | 72 | /min | S |
| 1915-09-21 | Respiratory rate | 14 | /min | S |
| 1915-09-21 | Body temperature | 36.6 | Cel | S |
| 1915-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1915-05-04 | Primary care visit for headaches, fatigue, and a very high blood pressure | finished | S |
| 1915-05-11 | One-week blood pressure and kidney safety check with nephrology consultation | finished | S |
| 1915-06-01 | Three-week check after losartan titration and dapagliflozin start | finished | S |
| 1915-06-29 | Four-week check after adding chlorthalidone | finished | S |
| 1915-10-26 | Six-month blood pressure and chronic kidney disease review | finished | S |
| 1915-08-10 | Same-day sick visit for low back pain | finished | S |
| 1915-09-21 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Treat severe hypertension without acute target-organ damage as an outpatient: start losartan and amlodipine together, check home blood pressure twice daily, and go to the emergency department for chest pain, shortness of breath, weakness, confusion, or vision loss | completed | GL-HTN-2025 | S |
| Nephrology referral for eGFR below 60 with severely increased albuminuria (UACR above 300 mg/g) and stage 2 hypertension | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Titrate losartan to the maximum tolerated dose and add an SGLT2 inhibitor for CKD with UACR of at least 200 mg/g; accept a creatinine rise of up to 30 percent | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021 | S |
| Add chlorthalidone if blood pressure stays above target on two agents; avoid NSAIDs and review every medication dose for kidney function | completed | GL-KDIGO-BP-2021, GL-HTN-2025 | S |
| Check potassium and creatinine one to four weeks after each renin-angiotensin, SGLT2 inhibitor, or diuretic change; then eGFR and UACR about three times a year for G3b A3, hemoglobin at least yearly, and calcium, phosphate, and PTH every six to twelve months; recalculate the kidney failure risk yearly | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| Moderate-intensity statin for an adult aged 50 or older with eGFR below 60; no routine repeat LDL | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Sodium below 2 g a day with a plan for meals while traveling; at least 150 minutes of activity a week | completed | GL-KDIGO-CKD-2024, GL-HTN-2025 | S |
| Annual dilated eye examination for hypertensive retinopathy; pneumococcal and hepatitis B vaccination for chronic kidney disease | completed | GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Lower blood pressure below 130/80 within two months | 1915-06-29 | completed | Blood pressure 128/80 on four medicines | S |
| Reach a standardized office systolic pressure below 120 when tolerated by the six-month review | 1915-10-26 | completed | Blood pressure 118/76 without dizziness | S |
| Reduce the urine albumin-creatinine ratio by at least 30 percent by the six-month review | 1915-10-26 | completed | UACR fell from 820 to 240 mg/g | S |
| Keep eGFR decline after starting therapy within 30 percent and stable thereafter | 1915-10-26 | completed | eGFR 36 at baseline, 30 on full therapy, 32 at six months | S |